司天梅;方贻儒;李涛;许秀峰;郝伟;徐一峰;贾福军;李惠春;杨甫德;刘铁榜;梅其一;宁玉萍;施慎逊;王高华;王向群;许毅;陆峥;张宁;于欣;赵靖平;李凌江;江开达;

• 1:北京大学第六医院药理研究室
• 2:卫生部精神卫生学重点实验室(北京大学)
• 3:上海交通大学医学院附属精神卫生中心心境障碍科
• 4:四川大学华西医院心理卫生中心

摘要(Abstract)：

米氮平是一种去甲肾上腺素能和特异性5-羟色胺能抗抑郁药。一系列上市前及上市后的临床研究结果显示米氮平能有效治疗各种严重程度的抑郁障碍,耐受性良好,对伴有焦虑、激越以及失眠的抑郁障碍患者可能更有优势;长期维持治疗可降低抑郁障碍的复发风险;作为增效药物联合治疗可有效治疗对其他抗抑郁药单药治疗效果不佳的患者,与其他抗抑郁药相比,失眠、焦虑和性功能不良反应的发生风险相对较低。最近新上市了口崩片剂型,为适合该药治疗的患者,提供了另一种服药途径选择。

关键词(KeyWords)： 米氮平;作用机制;抑郁症;临床疗效

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 司天梅;方贻儒;李涛;许秀峰;郝伟;徐一峰;贾福军;李惠春;杨甫德;刘铁榜;梅其一;宁玉萍;施慎逊;王高华;王向群;许毅;陆峥;张宁;于欣;赵靖平;李凌江;江开达;

参考文献(References)：

• [1]De Boer T.The pharmacologic profile of mirtazapine[J].J Clin Psychiatry,1996,57(Suppl 4):19-25.
• [2]Gelenberg AJ,Freeman MP,Markowitz JC,et al.Practice guideline for the treatment of patients with major depressive disorder,Third Edition[M].Washinton DC:American Psychiatric Publishing,2010:10.
• [3]Cipriani A,Furukawa TA,Salanti G,et al.Comparative efficacy and acceptability of 12 new-generation antidepressants:a multipletreatments meta-analysis[J].Lancet,2009,373(9665):746-758.
• [4]Thase ME,Nierenberg AA,Vrijland P,et al.Remission with mirtazapine selective serotonin reuptake inhibitors:a meta-analysis of individual patient data from 15 controlled trials of acute phase of treatment of major depression[J].Int Clin Psychopharmacol,2010,25(4):189-198.
• [5]Watanabe N,Omori IM,Nakagawa A,et al.Mirtazapine versus other antidepressive agents for depression[J].Cochrane Database Syst Rev,2011,7(12):CD006528.
• [6]Szegedi A,Jansen WT,van Willigenburg AP,et al.Early improvement in first 2 weeks as a predictor of treatment outcome in patients with major depression disorder:a meta-analysis including 6562 patients[J].J Clin Psychiatry,2009,70(3):344-353.
• [7]Montgomery SA,Reimitz PE,Zivkov M.Mirtazapine versus amitriptyline in the long-term treatment of depression:a double-blind placebo-controlled study[J].Int Clin Psychopharmacol,1998,13(2):63-73.
• [8]Wade A,Crawford GM,Angus M,et al.A randomized,doubleblind,24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care[J].Int Clin Psychopharmacol,2003,18(3):133-141.
• [9]Thase ME,Nierenberg AA,Keller MB,et al.Efficacy of mirtazapine for prevention of depressive relapse:a placebo-controlled double-blind trial of recently remitted high-risk patients[J].J Clin Psychiatry,2001,62(10):782-788.
• [10]Fava M,Dunner DL,Greist JH,et al.Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure:an open-label trial[J].J Clin Psychiatry,2001,62(6):413-420.
• [11]Fang Y,Yuan C,Xu Y,et al.Comparisons of the efficacy and tolerability of extended-release venlafaxine,mirtazapine,and paroxetine in treatment-resistant depression:a double-blind,randomized pilot study in a Chinese population[J].J Clin Psychopharmacol,2010,30(4):357-364.
• [12]Fava M,Rush AJ,Wisniewski SR,et al.A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients:a STAR*D report[J].Am J Psychiatry,2006,163(7):1161-1172.
• [13]Blier P,Ward HE,Tremblay P,et al.Combination of antidepressant medications from treatment initiation for major depressive disorder:a double-blind randomized study[J].Am J Psychiatry,2010,167(3):281-288.
• [14]Carpenter LL,Leon Z,Yasmin S,et al.Clinical experience with mirtazapine in the treatment of panic disorder[J].Ann Clin Psychiatry,1999,11(2):81-86.
• [15]Carpenter LL,Yasmin S,Price LH.A double-blind,placebo-controlled study of antidepressant augmentation with mirtazapine[J].Biol Psychiatry,2002,51(2):183-188.
• [16]Mendlewicz J.Sleep disturbances:core symptoms of major depressive disorder rather than associated or comorbid disorders[J].World J Biol Psychiatry,2009,10(4):269-275.
• [17]Schittecatte M,Dumont F,Machowski R,et al.Effects of mirtazapine on sleep polygraphic variables in major depression[J].Neuropsychobiology,2002,46(4):197-201.
• [18]Benkert O,Szegedi A,Kohnen R.Mirtazapine compared with paroxetine in major depression[J].J Clin Psychiatry,2000,61(9):656-663.
• [19]Wang D,Li Z,Li L,et al.Real-world,open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder[J].Asia Pac Psychiatry,2014,6(2):152-160.
• [20]Kim JE,Yoon SJ,Kim J,et al.Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms:an 8-week open-label randomised paroxetine-controlled trial[J].Int J Clin Pract,2011,65(3):323-329.
• [21]Schatzberg AF,Kremer C,Rodrigues HE,et al.Double-blind,randomized comparison of mirtazapine and paroxetine in elderly depressed patients[J].Am J Geriatr Psychiatry,2002,10(5):541-550.
• [22]Roose SP,Nelson JC,Salzman C,et al.Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home[J].Curr Med Res Opin,2003,19(8):737-746.
• [23]Benjamin S,Doraiswamy PM.Review of the use of mirtazapine in the treatment of depression[J].Expert Opin Pharmacother,2011,12(10):1623-1632.
• [24]Kasper S,Praschak-Rieder N,Tauscher J,et al.A risk-benefit assessment of mirtazapine in the treatment of5depression[J].Drug Saf,1997,17(4):251-264.
• [25]Radhakishun FS,van den Bos J,van der Heijden BC,et al.Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens[J].J Clin Psychopharmacol,2000,20(5):531-537.
• [26]Laimer M,Kramer-Reinstadler K,Rauchenzauner M,et al.Effect of mirtazapine treatment on body composition and metabolism[J].J Clin Psychiatry,2006,67(3):421-424.
• [27]Nutt DJ.Tolerability and safety aspects of mirtazapine[J].Hum Psychopharmacol,2002,17(Suppl 1):S37-41.
• [28]Larsen JK,Bendsen BB,Bech P.Vitamin B6 treatment of oedema induced by mirtazapine and isocarboxazid[J].Acta Psychiatr Scand,2011,124(1):76-77.
• [29]Dholakia R,Schleifer SJ,Ahmad YJ,et al.Delayed-onset mirtazapine-related leukopenia and rechallenge[J].J Clin Psychopharmacol,2010,30(6):758.
• [30]Anghelescu I,Klawe C,Dahmen N.Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia[J].J Clin Psychiatry,2002,63(9):838.
• [31]Spina E,Santoro V,D'Arrigo C.Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants:an update[J].Clin Ther,2008,30(7):1206-1227.
• [32]Heuvel MW,Kleijn HJ,Peeters PAM.Bioequivalence Trial of Orally Mirtazapine Tablets and Conventional Oral Mirtazapine Tablets in Healthy Volunteers[J].Clin Drug Invest,2001,21(6):437-442.
• [33]Delini-StulaA,OersHV,WilligenburgAV,et al.The results of the Swiss observational study of the newfastdissolving mirtazapine formulation in depressed patients[J].Int J Clin Pract,2009,13(2):109-116.